Study of a HPV vaccine among 9-11 year-old girls
Do you have a daughter between the ages of 9 and 11 years of age? Researchers at the University of Arizona are conducting a HPV vaccine study that may interest you! HPV is short for human papillomavirus, a common virus. HPV vaccines are usually given as a series of three injections over 6 months to protect against HPV-related cancers and diseases. This new HPV vaccine study is recruiting 9-11 year-old girls to determine if one injection of the HPV vaccine will produce long-term immune response. Girls who participate in the study will receive Gardasil® 9, an FDA-approved HPV vaccine that offers the widest protection, at no cost and will receive the 2nd and 3rd injections of the vaccine later than the current schedule. Blood tests will be done to check for immune protection against HPV. Girls and their guardians will receive monetary compensation for participating in this study. This study is sponsored by the National Institutes of Health. The study should help reduce HPV-related cancers and diseases in our communities and around the globe. Please contact the study team at (520) 425-9351 if you are interested in more information.
Study phase: II
Basic eligibility criteria:
Please contact the study coordinator for additional eligibility information.
Healthy, medically well girls aged 9-11
No previous HPV vaccination
Not receiving treatment for cancer or autoimmune condition
No allergy to yeast
Primary disease category: Children, Infants & Newborns
This study is enrolling healthy volunteers.
Projected enrollment dates: May 2016 to May 2020
Official study title: A prospective, single-arm, open-label, non-randomized, phase IIA trial of a nonavalent prophylactic HPV vaccine to assess immunogenicity of a prime and deferred-booster dosing schedule among 9-11 year-old girls